The has issued an against , effectively restraining the company from manufacturing, marketing, or selling its medicinal product ‘NO-CINV’. The ruling comes in response to a initiated by the Swiss-based and its Indian exclusive licensee, who claimed that the generic drug violates their rights under Indian Patent No. 426553. This patent, which relates to an orally administered dosage form for treating chemotherapy-induced nausea and vomiting (CINV), remains valid and subsisting until . The court's order serves to maintain the until the next hearing, preventing the further dissemination of the in the Indian market.
The dispute originated when the plaintiffs, after learning of a proposed launch via a market survey, discovered that the defendant was preparing to market a combipack containing Netupitant and Palonosetron—the very combination protected by the suit patent. Although the defendant, Intas Pharmaceutical, argued that these active ingredients are known substances and that their combination does not constitute an invention, the court found the infringement to be evident. The plaintiffs had previously launched their own formulation, ‘AKYNZEO’, in India in , establishing a significant market presence that they argued would be irreparably harmed by the defendant's launch of ‘NO-CINV’.
In its assessment, the court emphasized the professional background of the defendant, noting that Intas is an established player in the pharmaceutical industry with extensive experience in navigating the legal requirements of intellectual property rights. The bench highlighted that despite the patent having been granted in following a rigorous process—including the rejection of multiple —the defendant had failed to initiate any legal proceedings to challenge the patent's validity before proceeding with its product launch.
Commenting on this lack of procedural diligence, the court observed:
"The Defendant has, therefore, proceeded to manufacture and launch the
without first seeking to ‘
’ as contemplated in law."
This principle, which requires companies to challenge the validity of a patent before entering a market if they believe the patent is vulnerable, was a critical factor in the court's decision. By ignoring this standard practice, the defendant accepted the risks associated with potential infringement. The court noted that because the issue of whether a combination of known substances lacks novelty requires a deep, evidence-backed examination of technical specifications and claims, it could not be resolved at this preliminary stage.
The court's decision was further bolstered by the findings in a similar matter involving another pharmaceutical entity, where the court had previously determined that packaging two distinct, patented components into a single integrated combipack does not negate the defense of infringement. Relying on this logic, the bench noted that the defendant’s attempt to characterize the product as two separate tablets did not undermine the plaintiffs'
case.
"This Court cannot lose sight of the material fact that the Defendant itself is an established pharmaceutical company,"
the judge remarked, pointing out that Intas was well-versed in the legal mechanisms available for contesting patent grants, yet chose not to utilize them.
Regarding the urgency of the matter, the plaintiffs were commended for their quick response, having approached the court within 48 hours of discovering the defendant's market preparations. This "" played a significant role in the court’s decision to grant the interim protection. The court found that because the product was manufactured only recently and had not yet gained significant market penetration, restraining its sale would not cause the defendant excessive prejudice, whereas the continued sale of the product would cause to the plaintiffs' market interests.
Addressing the potential harm, the court stated:
"The
lies in favour of the Plaintiffs, and the Plaintiffs are likely to suffer
in case the Defendant is permitted to continue dealing in the
."
Consequently, the injunction covers all aspects of the defendant's commercial activities, including manufacturing, exporting, distributing, and advertising the infringing product, until the next date of hearing.
The court has directed the defendant to file a detailed response by . This response must include specific supporting evidence, such as comprehensive sales invoices and airway bills evidencing the distribution of the product since its launch. Additionally, Intas is required to submit a detailed statement of its existing inventory, including batch numbers, manufacturing dates, and expiry information, all of which must be verified and signed by a director of the company.
While the current order provides temporary relief to the plaintiffs, the court explicitly clarified that its observations are only of a nature. This ensures that the defendant retains the right to raise all permissible defenses and present evidence to challenge the validity of the patent or the merits of the infringement claim when the matter is heard in full. The litigation is expected to continue with a focus on the technical merits of the patent claims and the validity of the combination invention. As the parties prepare for the next hearing, the case remains a significant reminder of the risks involved for generic pharmaceutical manufacturers who choose to enter the market without first clearing existing patent obstacles. The next hearing, scheduled before the roster bench, will determine whether the will be extended or vacated based on the pleadings to be filed by the defendant.
pharmaceutical patent infringement - ad-interim injunction